What just happened? TherapeuticsMD, Inc. (NASDAQ:TXMD) stock value has plummeted by nearly -2.46% or (-0.08 points) to $3.37 from its previous close of $3.45. Does this decline mean it the best stock to buy right now? The shares seem to have an active trading volume day with a reported 1169007 contracts so far this session. TXMD shares had a relatively better volume day versus average trading capacity of 3.19 million shares, but with a 0.2 billion float and a -2.82% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for TXMD stock indicates that the average analyst price target is $16 per share. This means the stock has a potential increase of 374.78% from where the TXMD share price has been trading recently which is between $3.25 and $3.58. There are some brokerage firms that offer lower targets than the average, with one of them, even setting their price target at $4.
The shorts are climbing into TherapeuticsMD, Inc. (TXMD) stock. The latest set of short interest data was released on 30 April 2019, and the numbers show a rise in short interest in TXMD shares. While short interest still represents only 39.01% of TXMD’s float, the number of shares shorted have risen by 1902885. The number of shares shorted advanced to 79298575 shares, up from 77395690 shares during the preceding fortnight. With average daily trading volumes at 2760062 shares, days to cover decreased to about 40.28334 days. The most recent news story about the stock that appeared in Yahoo Finance‘s news section was titled “Edited Transcript of TXMD earnings conference call or presentation 6-May-19 8:30pm GMT” and dated May 10, 2019.
During the recent trading session for TherapeuticsMD, Inc. (NASDAQ:TXMD), the company witnessed their stock drop by $-0.09 over a week and tumble down $-0.87 from the price 20 days ago. When compared to their established 52-week high of $7.66, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 06/08/18. The recent low of $3.19 stood for a -56.07% since 05/14/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 2.03 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.
Looking at the current readings for TherapeuticsMD, Inc., the two-week RSI stands at 27.55. This figure suggests that TXMD stock, for now, is overbought, meaning that the shares are not stable in terms of price movement. The stochastic readings, on the other hand, based on the current TXMD readings is similarly very revealing as it has a stochastic reading of 10.89% at this stage. This figure means that TXMD share price today is being overbought.
Technical chart claims that TherapeuticsMD, Inc. (TXMD) would settle between $3.6/share to $3.76/share level. However, if the stock price goes below the $3.27 mark, then the market for TherapeuticsMD, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $3.1 for its downside target. The stock is currently in the red zone of MACD, with the indicator reading -0.11. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at Noble Capital Markets, assumed coverage of TXMD assigning Outperform rating, according to their opinion released on April 30. JP Morgan, analysts launched coverage of TherapeuticsMD, Inc. (NASDAQ:TXMD) stock with a Overweight recommendation, according to their flash note issued to investors on June 15. Analysts at Morgan Stanley, made their first call for the equity with a Equal-Weight recommendation, according to a research note that dated back to September 08.
TXMD equity has an average rating of 1.86, with the figure leaning towards a bullish end. 7 analysts who tracked the company were contacted by Reuters. Amongst them, 1 rated the stock as a hold while the remaining 6 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 6 analysts rated TherapeuticsMD, Inc. (NASDAQ:TXMD) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.
Moving on, TXMD stock price is currently trading at 0X forward 12-month Consensus EPS estimates, and its P/S ratio is 51.14 while for the average stock in the same group, the multiple is 7.19.
TherapeuticsMD, Inc. (TXMD)’s current-quarter revenues are projected to climb by nearly 91.76% to hit $7.21 million, based on current Zacks Consensus Estimate. The firm’s full-year revenues are expected to expand by over 145.25% from $16.1 million to a noteworthy $39.49 million. At the other end of the current quarter income statement, TherapeuticsMD, Inc. is expected to see its adjusted earnings surge by roughly -13.33% to hit $-0.17 per share. For the fiscal year, TXMD’s earnings are projected to climb by roughly -8.47% to hit $-0.64 per share.